BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 15028406)

  • 21. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.
    Sanguineti G; Richetti A; Bignardi M; Corvo' R; Gabriele P; Sormani MP; Antognoni P
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):762-71. PubMed ID: 15708255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.
    Beckmann GK; Hoppe F; Pfreundner L; Flentje MP
    Head Neck; 2005 Jan; 27(1):36-43. PubMed ID: 15459918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3.
    Terhaard CH; Kal HB; Hordijk GJ
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):62-9. PubMed ID: 15850903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.
    Al-mamgani A; Tans L; Van rooij PH; Noever I; Baatenburg de jong RJ; Levendag PC
    Acta Oncol; 2009; 48(4):562-70. PubMed ID: 19373698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy.
    Corry J; Rischin D; Mukesh BN; Porceddu S; Peters LJ
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1416-22. PubMed ID: 15817345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume.
    Chao KS; Ozyigit G; Blanco AI; Thorstad WL; Deasy JO; Haughey BH; Spector GJ; Sessions DG
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):43-50. PubMed ID: 15093897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma.
    Lavaf A; Genden EM; Cesaretti JA; Packer S; Kao J
    Cancer; 2008 Feb; 112(3):535-43. PubMed ID: 18076014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
    Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma.
    Lu JJ; Kong L; Shakespeare TP; Loh KS; Zhang Q; Tan KS; Lee KM
    Oral Oncol; 2008 Jul; 44(7):703-9. PubMed ID: 18061528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
    Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer.
    Malone JP; Stephens JA; Grecula JC; Rhoades CA; Ghaheri BA; Schuller DE
    Head Neck; 2004 Jul; 26(7):561-72. PubMed ID: 15229898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03.
    Rabinovitch R; Grant B; Berkey BA; Raben D; Ang KK; Fu KK; Cooper JS;
    Head Neck; 2006 Apr; 28(4):287-96. PubMed ID: 16287132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative radiotherapy for primary mucosal melanoma of the head and neck.
    Temam S; Mamelle G; Marandas P; Wibault P; Avril MF; Janot F; Julieron M; Schwaab G; Luboinski B
    Cancer; 2005 Jan; 103(2):313-9. PubMed ID: 15578718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Base-of-tongue carcinoma: treatment results using concomitant boost radiotherapy.
    Mak AC; Morrison WH; Garden AS; Ang KK; Goepfert H; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):289-96. PubMed ID: 7673016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
    Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS
    J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.